Bone health and aldosterone excess.

Area of Science:

• Endocrinology
• Metabolic Bone Disease
• Mineral Metabolism

Background:

• Aldosterone excess in primary aldosteronism (PA) increases urinary calcium excretion, leading to hypocalcemia and secondary hyperparathyroidism.
• This condition can result in diminished bone mineral density (BMD).
• Treatment for PA, including surgery or medication, has shown potential to reverse these effects.

Purpose of the Study:

• To investigate calcium and phosphate metabolism in PA patients compared to essential hypertension (EH).
• To assess the impact of treating aldosterone excess on bone health in PA patients.

Main Methods:

• A study involving 226 patients: 116 with PA and 110 with EH.
• Biochemical parameters and bone mass were evaluated in 40 PA patients before and after a mean 24-month follow-up post-treatment.
• Dual-energy X-ray absorptiometry (DXA) was used to assess bone mineral density.

Main Results:

• PA patients exhibited higher parathyroid hormone (PTH) levels and urinary calcium excretion, with lower serum calcium, compared to EH patients.
• Following treatment, PA patients showed significantly reduced PTH levels and improved BMD at the lumbar spine, femoral neck, and total hip.
• These improvements in BMD occurred despite stable vitamin D levels.

Conclusions:

• The findings confirm secondary hyperparathyroidism in PA, which is reversible upon effective treatment.
• Targeted treatment for PA significantly improves bone mineral density at both spinal and hip sites.